Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.45M fell 14.9% year over year, ahead of the -39.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.
Context
- Stock-based compensation amounted to 9.5% of revenue in FY2025.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -14.9% holds above the trailing-twelve-month pace of -39.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.63M USD
- Year-over-year change
- -37.6%
- 4-year CAGR
- -17.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.63M | -37.6% |
| FY2024 | 2024-12-31 | 10.63M | +10.7% |
| FY2023 | 2023-12-31 | 9.6M | -21.3% |
| FY2022 | 2022-12-31 | 12.2M | -13.1% |
| FY2021 | 2021-12-31 | 14.04M | — |
Stock-Based Compensation vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.9% is the 10th highest of 11, against a peer median of +20.3%.
- Over three fiscal years its annual growth of -18.4% compares with a peer median of +20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $15.77M USD | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $13.96M USD | +64.9% | +21.7% | 23652.5% | |
| LTM Mar 2026 | $11.51M USD | -28.1% | +4.4% | 5116.0% | |
| LTM Mar 2026 | $11.16M USD | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $8.33M USD | +7.1% | +52.3% | 57.3% | |
| LTM Mar 2026 | $7.36M USD | +42.2% | — | 26.1% | |
| LTM Mar 2026 | $6.38M USD | -39.9% | -18.4% | — | |
| LTM Mar 2026 | $6.24M USD | +33.6% | +18.6% | 12.2% | |
| LTM Mar 2026 | $2.64M USD | +336.0% | +112.4% | — | |
| LTM Mar 2026 | $1.52M USD | -69.5% | — | — | |
| Peer median (excluding BDTX) | — | +20.3% | +20.1% | 78.4% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| Deferred Income Tax | 2.18M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M |
| Change in Working Capital | 7.02M | (9.9M) | 3.69M | (2.69M) | (8.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (2.23M) | 597K | 1.68M | (3.43M) |
| Other Working Capital | 5.45M | (7.67M) | 3.09M | (4.38M) | (5.3M) |
| Other Non-Cash Items | 2.01M | 3.28M | 2M | (905K) | 9.02M |
| Operating Cash Flow | (100.15M) | (85.08M) | (66.72M) | (62.3M) | 29.61M |
| Capital Expenditures | (2.71M) | (192K) | (33K) | 0 | 0 |
| Acquisitions (Net) | 2.7M | 9K | 0 | 94K | 27K |
| Purchases of Investments | (49.51M) | (60.14M) | (61.89M) | (122.88M) | (164.03M) |
| Sales of Investments | 182.83M | 113.69M | 78.17M | 139.75M | 119.02M |
| Other Investing Activities | (2.7M) | 0 | 95K | 0 | 74K |
| Investing Cash Flow | 130.61M | 53.37M | 16.35M | 16.97M | (44.91M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 729K | 177K | 71.85M | 24.49M | (146K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 82K | 1.05M | 0 |
| Financing Cash Flow | 729K | 177K | 71.93M | 25.55M | (146K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.19M | (31.54M) | 21.56M | (19.79M) | (15.44M) |
| Free Cash Flow | (102.86M) | (85.27M) | (66.75M) | (62.3M) | 29.61M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.